Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

Applications Due: Closed
Federal
US Department of Health & Human Services (National Institutes of Health)

This funding opportunity supports research into how certain diabetes medications may influence cancer risk, encouraging studies that explore the underlying biological mechanisms involved.

Description

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Eligibility
States
All
Regions
All
Eligible Entities
State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal organizations, Public housing authorities, Native American tribal organizations, Nonprofits

Funding

Program Funding
Visit Source
Award Ceiling
Visit Source
Award Floor
Visit Source
Award Count

Timing

Posted Date
August 23, 2023
App Status
No Longer Accepting Applications
Pre-app Deadline
Visit Source
Application Deadline
November 17, 2024

Funder

Funding Source
Visit Source
Source Type
Federal
Contact Name
NIH Grants Information
Contact Email
Click to email
Contact Phone
--

Why Organizations Trust GrantExec

$78.81B
Available Funding
7,151
Active Grants
224
New Grants Analyzed This Week